Related Experiment Video
Updated: Mar 15, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
10.4K
[Radiotherapy for soft tissue sarcomas: Technical evolution and impact on clinical benefit]
C Llacer-Moscardo1, C Bourgier1, A Morel1
1Département de radiothérapie oncologique, institut du cancer de Montpellier (ICM), 208, avenue des Apothicaires, parc Euromédecine, 34298 Montpellier cedex 5, France.
Summary
Standard extremity soft tissue sarcoma treatment combines surgery and radiotherapy, but identifying patients who benefit most is key. Advanced radiotherapy techniques aim to reduce toxicity and improve outcomes for high-risk cases.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Extremity soft tissue sarcomas are typically treated with surgery and radiotherapy.
- This combined approach enhances local control but carries a risk of increased toxicity.
- Identifying patients who specifically benefit from radiotherapy is crucial for personalized treatment.
Purpose of the Study:
- To explore strategies for optimizing radiotherapy use in soft tissue sarcoma treatment.
- To discuss methods for reducing treatment-related toxicity.
- To review advancements in radiotherapy technology for improved patient outcomes.
Main Methods:
- Review of current treatment paradigms for extremity soft tissue sarcomas.
- Discussion of the relationship between radiation dose, volume, and toxicity.
- Examination of technological advancements in radiotherapy, including intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT).
Main Results:
- Radiotherapy selection can be refined to target patients most likely to benefit.
- Treatment toxicity is linked to irradiated volume and high-dose regions.
- Advanced techniques like IMRT and IGRT can minimize irradiated volumes and protect organs at risk.
Conclusions:
- Personalizing radiotherapy in soft tissue sarcoma treatment can improve clinical benefits.
- Technological advancements offer improved toxicity profiles and organ protection.
- Ongoing efforts focus on enhancing local control for patients with a high risk of relapse.
Related Concept Videos
02:49Cancer Therapies
10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K